Clinical Trial Detail

NCT ID NCT04348747
Title Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

Her2-receptor positive breast cancer

triple-receptor negative breast cancer

Therapies

Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod

Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod

Age Groups: senior adult

No variant requirements are available.